Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.
about
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infectionCerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentInteraction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System DiseaseDisturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric SymptomsFactors in AIDS dementia complex trial design: results and lessons from the abacavir trialClinical Trials in Neurovirology: Successes, Challenges, and PitfallsNeurocognitive function in HIV-positive children in a developing country.Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohortsCerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection.The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.HIV-1 replication in the central nervous system occurs in two distinct cell types.Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.Central nervous system infection during immunosuppression.Neurocognitive function in HIV infected patients on antiretroviral therapyCerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot studyRaltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyQuantifying cognition at the bedside: a novel approach combining cognitive symptoms and signs in HIV.Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials.The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study.The cerebrospinal fluid proteome in HIV infection: change associated with disease severityCognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infectionNanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Expanded HIV testing coverage is associated with decreases in late HIV diagnoses.Antiretroviral therapy and central nervous system HIV type 1 infectionNeurologic signs and symptoms frequently manifest in acute HIV infection.PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDSImpact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.HIV-associated neurological disorders: a guide to pharmacotherapy.Improvements in brain and behavior following eradication of hepatitis C.Diagnostic utility of the HIV dementia scale and the international HIV dementia scale in screening for HIV-associated neurocognitive disorders among Spanish-speaking adults.Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS.A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.Prevalence of depressive and other central nervous system symptoms in HIV-infected patients treated with HAART in Spain.
P2860
Q24810504-D50E77FF-C227-476B-8705-D4128F2253FDQ24814874-E6F1B94B-A7DC-4C7F-BE3B-AFDB0C6FBFECQ26770397-6F47FBFA-7BEB-4943-8A48-F19EE103DBF3Q26800052-C0C82E0F-8382-4CB4-AB29-C91627D47EDDQ28469174-CF5461FB-3A90-4B12-82D4-356473AD6CD0Q30250271-5AFFBF42-043C-4F6F-A0E6-DAC779DCBC25Q33754219-71843B16-4368-4E5C-97FB-457F5B54DE48Q33792332-907B42C4-F60D-4D17-92F1-AA89C8CAC572Q33933507-83AD5432-CA24-407E-A3C5-C74E95197D83Q33938797-0723C87C-942C-498F-B2D1-56C3D743B5C8Q34033558-4DD94DC5-9ACC-4A7A-8C00-51A3633940C5Q34050421-665F5F7F-1A78-4D3E-BE23-BFAD7F40A8ECQ34125560-FD0CDCD7-A59F-4FB5-8D45-2D385BAD5D11Q34161535-C4FCBE0D-8924-4EFF-88E0-C4EAC93D337EQ34469041-4889219E-23C4-4FDF-A60F-EAB2E3CCD0ECQ34706686-F1A94753-3FCE-4E7B-9ECB-C2EBD6E983FBQ34776835-9796DF96-A70D-4BF9-A8F2-961E74D6DD09Q35052651-A2E6F7D9-44D9-478E-A06E-193D099DF416Q35532868-5E2F96ED-AEE1-4997-986E-137F80902DE1Q35840202-0620125A-3755-4884-A5D4-7469B8505750Q35877689-E4FA93F5-45E1-4EE7-8476-37DD634C6BB0Q35893079-7D559E1A-CFA7-41E2-9826-FADB8D443486Q35945958-8C5ADCD9-622C-4BA4-A308-AB78B4DE1D4CQ35965332-D74B7F0E-CD49-44D7-8BC7-405D16A4963EQ36408171-FBC2F098-CACE-4808-BF46-150CCA04B1A1Q36583732-055E8BEF-EBA6-4521-80D0-72CBAE95223FQ36976947-F837E3FE-D822-43B0-9D33-DF6A29CFD6D6Q37066982-3D2B9FD8-DBE6-40AA-9177-FC2739C66A68Q37082935-176A0809-EF8D-476F-8863-15189DB0C66AQ37221685-A9EB02D9-D983-409A-A63C-87BFC804BE12Q37252459-0F63B4FF-96D6-4068-8AFB-EFA96C85252EQ37362071-1A0AA656-C7FF-49F3-BC26-601AE9F0C612Q37659348-EA3A4A2D-9C00-49AB-9D00-CE6F30842CC4Q37971469-C8BFB8DD-ABD3-434B-9898-61F813E05EA2Q38676897-E2544EE3-CDB9-4C8D-A7F4-9115C89F00A3Q40514849-C9405F4B-15DB-4FA2-A993-2F4E4D89EBF6Q43698456-B8D78DF7-D5A6-4F63-AE46-CDB1DC7AB257Q44746049-2878D335-B9FF-41F0-A483-9B951383B5B8Q45415273-8801B57B-F4CB-46D1-B722-468BA15882F2Q48237619-92D302E2-5AF3-402E-8C9A-8039DD9363B1
P2860
Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Neurological outcomes in late ...... esearch Consortium study team.
@en
type
label
Neurological outcomes in late ...... esearch Consortium study team.
@en
prefLabel
Neurological outcomes in late ...... esearch Consortium study team.
@en
P2093
P1433
P1476
Neurological outcomes in late ...... esearch Consortium study team.
@en
P2093
Clifford DB
Yiannoutsos CT
Zaborski L
P304
P356
10.1097/00002030-199909100-00011
P407
P577
1999-09-01T00:00:00Z